Transasia Bio-medicals’ International Hematology Range Backed By European R&d Is Now In Telangana;

By Author: Anurag David
Total Articles: 467
Comment this article

Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Telangana; eyes 300 crores in FY2019-20 from hematology in Indian market
Priced 25% below comparable options, the new range will make world-class diagnostics affordable for the masses in Telangana
Hyderabad April 13, 2019: Transasia Bio-Medicals Ltd., India's No. 1 In-vitro Diagnostic (IVD) Company and among the leading global players focused on emerging markets, today as part of its 40th anniversary celebration announced that its international hematology range, is now available in Telangana. Backed by European R&D, the 3-Part Differential (3PD) to 5-Part Differential (5PD) fully automated haematology analyzers, reagents and controls include a number of features to help institutions, clinicians and lab technologists offer accurate diagnosis. Manufactured by Erba Lachema (100% owned subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580 hematology analyzers are widely used in the European market. Hematology analyzers are extensively used in patient and research settings to count and characterize blood cells ...
... for disease detection and monitoring. Basic analyzers return a complete blood count (CBC) with a three-part differential white blood cell (WBC) count. Sophisticated analyzers measure cell morphology and can detect small cell populations to diagnose rare blood conditions. The new hematology range are relevant for Telangana, where recent studies have shown growing number of children born have unique and high incidence of hemoglobinopathies like thalassemia and sickle cell anemia. Especially Nizamabad, Adilabad and Warangal, where the custom of consanguineous marriages has caused a rise in the number of thalassemic babies. Screening of all pregnant women helps in early detection and that’s where Transasia’s hematology range comes in.
Addressing the media, Suresh Vazirani, Chairman & Managing Director, Transasia Bio-Medicals Ltd., said, “Telangana is very close to our heart as Hyderabad is where we established our first zonal office in India and also sold our first cell counter in 1983. 3-4 years ago, the Telangana State Medical Services Infrastructure Development Corporation (TSMSIDC), which was established for equitable access to drugs and diagnostic services, especially in the interiors of the state, trusted Transasia by purchasing 5 part differential haematology analyzers for 13-15 medical college hospitals in remote areas. Today every district hospital in Telangana has a Transasia equipment. That is how closely we have been associated with serving the people of the state and we hope with the new range that this close association only grows further. We are encouraged by the initial response to the new range and will be targeting Rs. 300 crores in revenues from Indian market this fiscal.”
India ranks 145th among 176 countries on the quality and accessibility of healthcare parameter. Limited access to quality medical infrastructure, including skilled manpower and technologies have been the pain points of over 70%

of Indians who live in smaller towns and rural areas. Transasia has been focusing on indigenous development & technology adoption which facilitates affordable diagnostics through domestic manufacturing.
Talking about the newly launched range, Alastair McLeod, Vice President - Global Marketing - Erba Group, UK, said, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs. The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
Added Suresh Vazirani, “As per industry reports in 2018, India's medical devices industry is pegged at a $5.2 billion (Rs. 35,097.40 crore), most of which is imported. It is players like Transasia who are at the forefront of changing it and driving Make in India.”
About Transasia Bio-Medicals Ltd.: Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. Transasia provides doctors and patients with reliable, affordable and innovative Medical Diagnostic Systems, with an impressive install base of above 65,000 equipment across India. It has a vast network of the more than 250 service engineers, 400+ sales and marketing team, 23 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s. Today, Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world. All along its journey spanning more than four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device - Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum amongst many others. Headquartered in Mumbai, Transasia is a part of the global Transasia-Erba group. The group has spread its footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions. Transasia-Erba Group’s production sites in India, Czech Republic and USA and R&D centres in France, UK, India and Czech Republic form a hub for indigenous manufacturing of world class deliverables. Today, the group serves millions across 100 countries. For further information, kindly visit www.erbamannheim.com
For editorial queries only contact: